恶性胶质瘤的溶瘤细菌治疗
Oncolytic bacteria therapy for malignant glioma.
摘要(中文译文)
恶性胶质瘤是一组预后极差的中枢神经系统原发性恶性肿瘤，其中胶质母细胞瘤恶性程度最高。其高度侵袭性、肿瘤异质性、顽固的免疫抑制微环境以及血脑屏障的阻隔效应，导致传统手术、放疗和化疗疗效有限，复发率高、生存期短。肿瘤缺氧微环境作为胶质瘤治疗抵抗和复发的核心原因，也为新型靶向治疗提供了天然治疗靶点。溶瘤细菌作为一种新兴的肿瘤生物治疗技术，凭借其天然的肿瘤缺氧靶向性、自主增殖能力、多重抗肿瘤机制及灵活的基因改造潜力，能够特异性定植于胶质瘤深部缺氧区域，直接裂解肿瘤细胞，重塑肿瘤免疫微环境，并突破血脑屏障药物递送瓶颈，成为攻克胶质瘤治疗难题的研究热点。本文系统综述了溶瘤细菌的核心菌株特性、抗肿瘤分子机制、基因工程与合成生物学改造策略，总结了临床前研究成果及早期临床试验进展，深入分析了当前临床转化面临的核心挑战，如生物安全性、递送效率和疗效评价等，并结合多学科交叉技术展望了未来发展方向，旨在为深化溶瘤细菌在恶性胶质瘤领域的基础研究与临床转化提供全面的理论支撑和实践参考。
Abstract
Malignant glioma is a group of primary malignant tumors of the central nervous system with an extremely poor prognosis, with glioblastoma being the most malignant type. Its highly invasive nature, tumor heterogeneity, stubborn immunosuppressive microenvironment, and the barrier effect of the blood-brain barrier result in limited efficacy of traditional surgery, radiotherapy, and chemotherapy, leading to high recurrence rates and short survival times. The tumor hypoxic microenvironment, as a core cause of treatment resistance and recurrence in glioma, also provides a natural therapeutic target for novel targeted therapies. Oncolytic bacteria, as an emerging tumor biotherapy technology, leverage natural tumor hypoxia targeting, autonomous proliferation capacity, multiple antitumor mechanisms, and flexible genetic modification potential. They can specifically colonize deep hypoxic areas of glioma, directly lyse tumor cells, remodel the tumor immune microenvironment, and overcome the bottleneck of drug delivery across the blood-brain barrier, making them a research hotspot for overcoming the challenges of glioma treatment. This article systematically reviews the core strain characteristics, antitumor molecular mechanisms, genetic engineering and synthetic biology modification strategies of oncolytic bacteria, summarizes preclinical research results and early clinical trial progress, deeply analyzes the core challenges currently faced in clinical translation, such as biosafety, delivery efficiency, and efficacy evaluation, and looks forward to future development directions combined with multidisciplinary cross-technologies, aiming to provide comprehensive theoretical support and practical references for deepening basic research and clinical translation of oncolytic bacteria in the field of malignant glioma.
如何引用
AMA
Feiyue Li, Jing Zhao, Ang Ji, Junlong Zhao, Sanzhong Li. Oncolytic bacteria therapy for malignant glioma.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1951763.
APA
Feiyue Li, Jing Zhao, Ang Ji, Junlong Zhao, Sanzhong Li (2026). Oncolytic bacteria therapy for malignant glioma.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1951763
GB/T 7714
Feiyue Li, Jing Zhao, Ang Ji, Junlong Zhao, Sanzhong Li. Oncolytic bacteria therapy for malignant glioma.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1951763.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出